Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes.
24-h ambulatory blood pressure monitoring
Office blood pressure
Renal function
Resistant hypertension
Safety
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
21
12
2023
accepted:
16
02
2024
pubmed:
7
3
2024
medline:
7
3
2024
entrez:
7
3
2024
Statut:
aheadofprint
Résumé
Randomized sham-controlled trials have confirmed the efficacy and safety of catheter-based renal denervation in hypertension. Data on the very long-term effects of renal denervation are scarce. This study evaluates the 10-year safety and efficacy of renal denervation in resistant hypertension. This prospective single-center study included patients with resistant hypertension undergoing radio-frequency renal denervation between 2010 and 2012. Office blood pressure, 24-h ambulatory blood pressure, antihypertensive medication, color duplex sonography, and renal function were assessed after 1-, 2- and 10-years. Thirty-nine patients completed the 10-year follow-up (mean follow-up duration 9.4 ± 0.7 years). Baseline office and 24-h ambulatory systolic blood pressure were 164 ± 23 mmHg and 153 ± 16 mmHg, respectively. After 10 years, 24-h ambulatory and office systolic blood pressure were reduced by 16 ± 17 mmHg (P < 0.001) and 14 ± 23 mmHg (P = 0.001), respectively. The number of antihypertensive drugs remained unchanged from 4.9 ± 1.4 to 4.5 ± 1.2 drugs (P = 0.087). The estimated glomerular filtration rate declined within the expected range from 69 (95% CI 63 to 74) to 60 mL/min/1.73m Renal denervation was safe and sustainedly reduced ambulatory and office blood pressure out to 10 years in patients with resistant hypertension.
Sections du résumé
BACKGROUND
BACKGROUND
Randomized sham-controlled trials have confirmed the efficacy and safety of catheter-based renal denervation in hypertension. Data on the very long-term effects of renal denervation are scarce.
AIMS
OBJECTIVE
This study evaluates the 10-year safety and efficacy of renal denervation in resistant hypertension.
METHODS
METHODS
This prospective single-center study included patients with resistant hypertension undergoing radio-frequency renal denervation between 2010 and 2012. Office blood pressure, 24-h ambulatory blood pressure, antihypertensive medication, color duplex sonography, and renal function were assessed after 1-, 2- and 10-years.
RESULTS
RESULTS
Thirty-nine patients completed the 10-year follow-up (mean follow-up duration 9.4 ± 0.7 years). Baseline office and 24-h ambulatory systolic blood pressure were 164 ± 23 mmHg and 153 ± 16 mmHg, respectively. After 10 years, 24-h ambulatory and office systolic blood pressure were reduced by 16 ± 17 mmHg (P < 0.001) and 14 ± 23 mmHg (P = 0.001), respectively. The number of antihypertensive drugs remained unchanged from 4.9 ± 1.4 to 4.5 ± 1.2 drugs (P = 0.087). The estimated glomerular filtration rate declined within the expected range from 69 (95% CI 63 to 74) to 60 mL/min/1.73m
CONCLUSION
CONCLUSIONS
Renal denervation was safe and sustainedly reduced ambulatory and office blood pressure out to 10 years in patients with resistant hypertension.
Identifiants
pubmed: 38451261
doi: 10.1007/s00392-024-02417-2
pii: 10.1007/s00392-024-02417-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Circ 138:e484–e594. https://doi.org/10.1161/CIR.0000000000000596
doi: 10.1161/CIR.0000000000000596
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339
doi: 10.1093/eurheartj/ehy339
pubmed: 30165516
Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD (2021) Hypertension control in the United States 2009 to 2018: factors underlying falling control rates during 2015 to 2018 across age- and race-ethnicity groups. Hypertension 78:578–587. https://doi.org/10.1161/HYPERTENSIONAHA.120.16418
doi: 10.1161/HYPERTENSIONAHA.120.16418
pubmed: 34120453
Johns EJ, Kopp UC, Dibona GF (2011) Neural control of renal function. Compr Physiol 1:731–767. https://doi.org/10.1002/cphy.c100043
doi: 10.1002/cphy.c100043
pubmed: 23737201
Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F (2020) Device-based therapies for arterial hypertension. Nat Rev Cardiol 17:614–628. https://doi.org/10.1038/s41569-020-0364-1
doi: 10.1038/s41569-020-0364-1
pubmed: 32286512
Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE et al (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 395:1444–1451. https://doi.org/10.1016/S0140-6736(20)30554-7
doi: 10.1016/S0140-6736(20)30554-7
pubmed: 32234534
Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S et al (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391:2346–2355. https://doi.org/10.1016/S0140-6736(18)30951-6
doi: 10.1016/S0140-6736(18)30951-6
pubmed: 29803589
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J et al (2018) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 6736:1–11. https://doi.org/10.1016/S0140-6736(18)31082-1
doi: 10.1016/S0140-6736(18)31082-1
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD et al (2019) Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. CIRC J 139:2542–2553. https://doi.org/10.1161/CIRCULATIONAHA.119.040451
doi: 10.1161/CIRCULATIONAHA.119.040451
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T et al (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 397:2476–2486. https://doi.org/10.1016/S0140-6736(21)00788-1
doi: 10.1016/S0140-6736(21)00788-1
pubmed: 34010611
Ahmad Y, Kane C, Arnold AD, Cook CM, Keene D, Shun-Shin M et al (2022) Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med 34:112–118. https://doi.org/10.1016/j.carrev.2021.01.031
doi: 10.1016/j.carrev.2021.01.031
pubmed: 33551282
pmcid: 8813172
Syed M, Osman M, Alhamoud H, Saleem M, Munir MB, Kheiri B et al (2021) The state of renal sympathetic denervation for the management of patients with hypertension: a systematic review and meta-analysis. Catheter Cardiovasc Interv 97:E438–E445. https://doi.org/10.1002/ccd.29384
doi: 10.1002/ccd.29384
pubmed: 33179863
Al GH, Götzinger F, Böhm M, Mahfoud F (2022) Arterial hypertension- Clinical trials update 2021. Nutr Metab Cardiovasc Dis 32:21–31. https://doi.org/10.1016/j.numecd.2021.09.007
doi: 10.1016/j.numecd.2021.09.007
pubmed: 34690044
Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M et al (2022) Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol 80(20):1871–1880. https://doi.org/10.1016/j.jacc.2022.08.802
doi: 10.1016/j.jacc.2022.08.802
pubmed: 36357087
Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE et al (2022) Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res 280–8. https://doi.org/10.1038/s41440-022-01042-8
Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE et al (2022) Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 399(10333):1401–1410. https://doi.org/10.1016/S0140-6736(22)00455-X
doi: 10.1016/S0140-6736(22)00455-X
pubmed: 35390320
Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J et al (2022) Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention 18(8):E677–E685. https://doi.org/10.4244/EIJ-D-22-00305
doi: 10.4244/EIJ-D-22-00305
pubmed: 35913759
pmcid: 10241283
Al Ghorani H., Kulenthiran S., Recktenwald MJM., Lauder L, Kunz M, Götzinger F et al (2023) 10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension. J Am Coll Cardiol 81(5):517–9. https://doi.org/10.1016/j.jacc.2022.11.038
Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG et al (2023) Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension 80(4):811–819. https://doi.org/10.1161/HYPERTENSIONAHA.122.20853
doi: 10.1161/HYPERTENSIONAHA.122.20853
pubmed: 36762561
Polonia J, Azevedo A, Monte M, Silva JA, Bertoquini S (2017) Annual deterioration of renal function in hypertensive patients with and without diabetes. Vasc Health Risk Manag 13:231–237. https://doi.org/10.2147/VHRM.S135253
doi: 10.2147/VHRM.S135253
pubmed: 28721063
pmcid: 5498504
Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF et al (2019) Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA 322:409–420. https://doi.org/10.1001/jama.2019.9811
doi: 10.1001/jama.2019.9811
pubmed: 31386134
pmcid: 6822661
Staplin N, Sierra A De, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M et al (2023) Relationship between clinic and ambulatory blood pressure and mortality : an observational cohort study in 59 124 patients. 6736(23):1–10. https://doi.org/10.1016/S0140-6736(23)00733-X
Weber MA, Schmieder RE, Kandzari DE, Townsend RR, Mahfoud F, Tsioufis K et al (2022) Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clin Res Cardiol 111(11):1269–1275. https://doi.org/10.1007/s00392-022-02064-5
doi: 10.1007/s00392-022-02064-5
pubmed: 35852582
pmcid: 9622517
Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP et al (2015) Reinnervation following catheter-based radio-frequency renal denervation. Exp Physiol 100:485–490. https://doi.org/10.1113/expphysiol.2014.079871
doi: 10.1113/expphysiol.2014.079871
pubmed: 25573386
Singh RR, McArdle ZM, Iudica M et al (2019) Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension 73:718–727. https://doi.org/10.1161/HYPERTENSIONAHA.118.12250
doi: 10.1161/HYPERTENSIONAHA.118.12250
pubmed: 30661475
Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP et al (2015) Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 65:393–400. https://doi.org/10.1161/HYPERTENSIONAHA.114.04176
Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K et al (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383:622–629. https://doi.org/10.1016/S0140-6736(13)62192-
doi: 10.1016/S0140-6736(13)62192-
pubmed: 24210779
Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, Böhm M et al (2020) Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv 13:471–484. https://doi.org/10.1016/j.jcin.2019.10.048
doi: 10.1016/j.jcin.2019.10.048
pubmed: 32081241
Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP et al (2020) Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention 16:89–96
doi: 10.4244/EIJ-D-19-00902
pubmed: 32038027
Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L et al (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 40:3474–3482. https://doi.org/10.1093/eurheartj/ehz118
doi: 10.1093/eurheartj/ehz118
pubmed: 30907413
pmcid: 6837160
Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK et al (2003) Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 42:1144–1149. https://doi.org/10.1161/01.HYP.0000101695.56635.31
doi: 10.1161/01.HYP.0000101695.56635.31
pubmed: 14597644
Chowdhury EK, Langham RG, Ademi Z, Owen A, Krum H, Wing LMH et al (2015) Rate of change in renal function and mortality in elderly treated hypertensive patients. Clin J Am Soc Nephrol 10:1154–1161. https://doi.org/10.2215/CJN.07370714
doi: 10.2215/CJN.07370714
pubmed: 25901093
pmcid: 4491290
Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V et al (2012) Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 7:401–408. https://doi.org/10.2215/CJN.07650711
doi: 10.2215/CJN.07650711
pubmed: 22282481
Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al (2000) Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646–661. https://doi.org/10.1053/ajkd.2000.16225
doi: 10.1053/ajkd.2000.16225
pubmed: 10977801
Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V et al (1999) Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 14(2):360–365. https://doi.org/10.1093/ndt/14.2.360
doi: 10.1093/ndt/14.2.360
pubmed: 10069189
Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C et al (2012) Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60(2):419–424. https://doi.org/10.1161/HYPERTENSIONAHA.112.193870
doi: 10.1161/HYPERTENSIONAHA.112.193870
pubmed: 22733462
Böhm M, Townsend RR, Kario K, Kandzari D, Mahfoud F, Weber MA et al (2020) Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medicat. Clin Res Cardiol 109:289–302. https://doi.org/10.1007/s00392-020-01595-z
doi: 10.1007/s00392-020-01595-z
pubmed: 32034481
pmcid: 7042193
Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D et al (2015) Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol 104:1097–1105. https://doi.org/10.1007/s00392-015-0905-5
doi: 10.1007/s00392-015-0905-5
pubmed: 26306594